Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.
Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.
复制标题
DOI：
10.1016/j.ygyno.2009.05.012
复制
发表时间：
2009-09
影响因子：
4.7
通讯作者：
Birrer MJ
中科院分区：
文献类型：
--
作者：
Darcy KM;Brady WE;Blancato JK;Dickson RB;Hoskins WJ;McGuire WP;Birrer MJ
妇科肿瘤组（GOG）研究了上皮性卵巢癌（EOC）中c-MYC扩增和多体性8的预后相关性。参与GOG-111（一项环磷酰胺+顺铂与紫杉醇+顺铂的多中心随机III期试验）并通过GOG-9404提供肿瘤阻滞的次优切除晚期EOC女性患者有资格入选。使用c-MYC和8号染色体着丝粒（CEP 8）探针进行荧光原位杂交（FISH），以检查c-MYC扩增（≥2个拷贝c-MYC/CEP 8）和8号多体性（≥4个CEP 8拷贝）。在29%（28/97）的EOC中观察到c-MYC扩增（定义为≥2个c-MYC/CEP 8拷贝），水平范围为2.0-3.3个c-MYC/CEP 8拷贝。c-MYC扩增与患者年龄、种族、GOG体能状态、分期、细胞类型、分级、手术后可测量的疾病状态、肿瘤缓解或铂类联合化疗后的疾病状态无关。与无c-MYC扩增的女性相比，有c-MYC扩增的女性疾病进展（风险比[HR] = 1.03; 95%置信区间[CI] = 0.65-1.64; p = 0.884）或死亡（HR = 1.08; 95% CI = 0.68-1.72; p = 0.745）的风险并未增加。c-MYC扩增不是无进展生存期（HR = 1.03，95% CI = 0.57-1.85; p = 0.922）或总生存期（HR = 1.01，95% CI = 0.56-1.80; p = 0.982）的独立预后因素。对于分类为≥1.5拷贝c-MYC/CEP 8的c-MYC扩增，获得了相似的不显著结果。在22名无c-MYC扩增的患者和3名有c-MYC扩增的患者中观察到8号多体性，并且与年龄和可测量的疾病状态相关，但与其他临床协变量或结局无关。c-MYC扩增和8型多体性对以铂类为基础的联合化疗治疗的次优切除、晚期EOC的预测或预后价值有限。
The Gynecologic Oncology Group (GOG) examined the prognostic relevance of c-MYC amplification and polysomy 8 in epithelial ovarian cancer (EOC). Women with suboptimally-resected, advanced stage EOC who participated in GOG-111, a multicenter randomized phase III trial of cyclophosphamide + cisplatin vs. paclitaxel + cisplatin, and who provided a tumor block through GOG-9404 were eligible. Fluorescence in situ hybridization (FISH) with probes for c-MYC and the centromere of chromosome 8 (CEP8) was used to examine c-MYC amplification (≥2 copies c-MYC/CEP8) and polysomy 8 (≥4 CEP8 copies). c-MYC amplification, defined as ≥2 copies c-MYC/CEP8, was observed in 29% (28/97) of EOCs and levels were ranged from 2.0–3.3 copies of c-MYC/CEP8. c-MYC amplification was not associated with patient age, race, GOG performance status, stage, cell type, grade, measurable disease status following surgery, tumor response or disease status following platinum-based combination chemotherapy. Women with vs. without c-MYC amplification did not have an increased risk of disease progression (hazard ratio [HR] = 1.03; 95% confidence interval [CI] = 0.65–1.64; p = 0.884) or death (HR = 1.08; 95% CI = 0.68–1.72; p = 0.745). c-MYC amplification was not an independent prognostic factor for progression-free survival (HR = 1.03, 95% CI = 0.57–1.85; p = 0.922) or overall survival (HR = 1.01, 95% CI = 0.56–1.80; p = 0.982). Similar insignificant results were obtained for c-MYC amplification categorized as ≥1.5 copies c-MYC/CEP8. Polysomy 8 was observed in 22 patients without c-MYC amplification and 3 with c-MYC amplification, and was associated with age and measurable disease status, but not other clinical covariates or outcomes. c-MYC amplification and polysomy 8 have limited predictive or prognostic value in suboptimally-resected, advanced stage EOC treated with platinum-based combination chemotherapy.
登录
查看更多内容
影响因子：
64.8
作者：
Dominguez-Sola, David;Ying, Carol Y.;Dalla-Favera, Riccardo
通讯作者：
Dalla-Favera, Riccardo
影响因子：
--
作者：
Fisher, RA
通讯作者：
Fisher, RA
影响因子：
6.4
作者：
BERNS, EMJJ;KLIJN, JGM;FOEKENS, JA
通讯作者：
FOEKENS, JA
影响因子：
8.8
作者：
Deming SL;Nass SJ;Dickson RB;Trock BJ
通讯作者：
Trock BJ
影响因子：
11.4
作者：
AMATI, B;LITTLEWOOD, TD;LAND, H
通讯作者：
LAND, H